# Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

> **NCT05453383** · PHASE2 · UNKNOWN · sponsor: **Shen Feng** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Cancer

## Interventions

- **DRUG:** Anlotinib;Toripalimab

## Key facts

- **NCT ID:** NCT05453383
- **Lead sponsor:** Shen Feng
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-08
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05453383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05453383, "Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05453383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*